- $137.05m
- -$42.83m
Brief: Compass Therapeutics Files For Up To $400 Million Mixed Shelf Offering- SEC Filing
Compass Therapeutics Q3 net loss widens to $14.3 mln
Compass Therapeutics dips after $120 mln equity offering
Brief: Compass Therapeutics Announces Pricing Of Upsized $120 Million Public Offering
Compass Therapeutics slides on stock offering launch
Compass Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Compass Therapeutics Q2 net loss widens to $19.9 mln
Brief: Compass Therapeutics To Present Second Quarter Financial Results
Compass Therapeutics Inc. expected to post a loss of 12 cents a share - Earnings Preview
Compass Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary
Compass Therapeutics Inc. expected to post a loss of 12 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Shake Shack, SatixFy, Enova
U.S. STOCKS ON THE MOVE-Shake Shack, SatixFy, Enova
Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms
U.S. STOCKS ON THE MOVE-Charles River Lab, Carvana, Materion
U.S. STOCKS ON THE MOVE-Travelers, Capri, Garmin
U.S. STOCKS ON THE MOVE-Bumble, Nikola, Diversified Energy
Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating
Brief: Compass Therapeutics Provides Corporate Update And Announces Advancement Of A New Drug Candidate